NCT05308212CompletedPhase 2
Multicenter, Double-blind, Comparative, Randomized Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra Inactivated Vaccine in Volunteers Aged 60 Years and Above
St. Petersburg Research Institute of Vaccines and Sera11 sites in 1 country633 target enrollmentStarted: March 4, 2021Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 633
- Locations
- 11
- Primary Endpoint
- Geometric mean titer (GMT) ratio of antibodies after vaccination
Study Overview
Brief Summary
Comparative assessment of the tolerability, safety, and immunogenicity of the FLU-M® Tetra quadrivalent inactivated split influenza vaccine and the Ultrix® vaccine in volunteers aged 60 years and above.
Detailed Description
Evaluation of the tolerability, safety and immunogenicity of the inactivated split influenza vaccine FLU-M® Tetra compared to Ultrix® vaccine in volunteers aged 60 years and above.
Volunteers were screened and randomized in three groups: the Flu-M Tetra w/p (with preservative) group, the Flu-M Tetra w/o/p (without preservative) group and the Ultrix® group. All subjects were followed up for 28 days post randomization and vaccination.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 60 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Volunteers (men and women) at the age of 60 years and above
- •Written informed consent of volunteers to participate in the clinical trial;
- •Volunteers able to fulfill requirements of the Protocol (i.e. fill out the patient's diary, come to follow-up visits);
- •For fertile women - a negative result of the pregnancy test and consent to observe adequate methods of contraception during the trial and at least two months after vaccination;
- •For fertile men - consent to observe adequate methods of contraception during the trial and at least two months after vaccination, except for men after vasectomy with documented azoospermia, and their sexual partners should use methods of contraception that ensure more than 90% reliability or be incapable of conception after a surgical sterilization or have a natural menopause for at least 2 years.
Exclusion Criteria
- •History of influenza/ARVI or previous influenza vaccination during 6 months before the trial;
- •Positive result of the SARS-CoV-2 test;
- •A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination);
- •Allergic reactions to vaccine components or any previous vaccination;
- •History of allergic reaction to chicken protein;
- •History of Guillain-Barré syndrome (acute polyneuropathy);
- •Previous vaccination with rabies vaccines less than 2 months before immunization or scheduled vaccination with rabies vaccines within 1 month after immunization with the trial vaccines;
- •History of leukemia, cancer, autoimmune diseases;
- •Positive blood test results for HIV, syphilis, hepatitis B/C.
- •Volunteers who received immunoglobulin or blood products or had a blood transfusion during the last three months before the trial;
- •History of long-term use (more than 14 days) of immunosuppressants or immunomodulatory drugs for six months before the trial;
- •History of any confirmed or suspected immunosuppressive or immunodeficiency condition;
- •History of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic, immune and endocrine system, mental disease in the acute stage or in the decompensation stage (recovery less than 4 weeks before vaccination);
- •History of eczema;
- •Treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (> 10 mg of prednisolone or its equivalent for more than 14 days before the screening);
- •Tuberculosis, neurological or mental disorders, a convulsive syndrome, including in the past medical history;
- •History of acute infectious diseases (recovery less than 4 weeks before vaccination);
- •Consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products;
- •Smoking of more than 10 cigarettes per day;
- •Participation in another clinical trial during the last 3 months;
- •Pregnancy or lactation;
- •Coagulopathy, haemophilia;
- •Taking aspirin or other antiplatelet agents in high doses.
Arms & Interventions
FLU-M Tetra w/p
Experimental
211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (with preservative) intramuscularly
Intervention: Flu-M Tetra [Inactivated split influenza vaccine] w/p (Biological)
FLU-M Tetra w/o/p
Experimental
211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Flu-M Tetra vaccine (without preservative) intramuscularly.
Intervention: Flu-M Tetra [Inactivated split influenza vaccine] w/o/p (Biological)
Ultrix
Active Comparator
211 volunteers aged 60 y.o. and older received a single intramuscular dose of the Ultrix vaccine.
Intervention: Ultrix [Inactivated split influenza vaccine] (Biological)
Outcomes
Primary Outcomes
Geometric mean titer (GMT) ratio of antibodies after vaccination
Time Frame: days 0, 28
Geometric mean titer (GMT) of antibodies in the blood serums of vaccinated people in haemagglutination inhibition assay.
Secondary Outcomes
- Change from baseline seroconversion rate at 28 days(days 0, 28)
- Frequency of development of SAEs associated with the vaccination(days 0-28)
- Results of assessment of respiratory rate (RR)(days 0,1,3,7,28)
- Number of participants with abnormal biochemical blood tests results(days 0,3)
- Number of participants with abnormal urinalysis results(days 0,3)
- Seroconversion factor(days 0, 28)
- Results of E immunoglobulin tests(days 0,3,28)
- Results of assessment of body temperature(days 0,1,3,7,28)
- Number of participants with abnormal neurological examinations(days 0,1,3,7,28)
- Seroprotection rate(days 0, 28)
- Frequency of development of AEs associated with the vaccination(days 0-28)
- Number of participants with abnormal ECG findings(days 0,3)
- Results of assessment of blood pressure (BP)(days 0,1,3,7,28)
- Number of participants with abnormal complete blood counts results(days 0,3)
- Number of participants with abnormal physical examination findings(days 0,1,3,7,28)
- Results of assessment of heart rate (HR)(days 0,1,3,7,28)
Investigators
Study Sites (11)
Loading locations...
Similar Trials
Completed
Phase 3
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 YearsFlu, HumanInfluenzaNCT05312294St. Petersburg Research Institute of Vaccines and Sera654
Completed
Phase 3
The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.InfluenzaNCT05317767St. Petersburg Research Institute of Vaccines and Sera600
Completed
Phase 3
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years OldInfluenza, HumanVaccinesInfection VaccinationNCT05470582St. Petersburg Research Institute of Vaccines and Sera1,066
Completed
Phase 2
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza VaccineVaccine ReactionInfection VaccinationInfluenza, HumanInfluenza Viral InfectionsInfluenzaNCT05869201St. Petersburg Research Institute of Vaccines and Sera450
Completed
Phase 3
Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant WomenInfluenza, HumanVaccinesInfection VaccinationNCT05457894St. Petersburg Research Institute of Vaccines and Sera207